Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for A Phase III Randomized Trial Comparing Adjuvant MK3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
The purpose of this Phase III study is to compare Overall Survival (OS) and Recurrence Free Survival (RFS) across the two arms: MK3475 (Pembrolizumab) to Standard of Care Observation. Patients will undergo standard clinical procedures including physical, labs, vitals, ecg's, and imaging.
Patients must have an ECOG performance Status: 0, 1, or 2 Patient must have a histological confirmation of diagnosis of Merkel cell carcinoma (MCC), pathologic stages (AJCC version 8) I-IIIb. completely resected by surgery within 8 weeks before enrollment. All patients must have disease-free status documented by a complete physical examination and conventional imaging studies within 4 weeks prior to randomization. Patients must not be on active immunosuppression, have a history of life threating virus, have had other cancer diagnoses in the last two years
Exclusion Criteria:
Women who are pregnant present metastases previous systemic therapy or radiation therapy for Merkel cell carcinoma. inoperable disease who have received radiation are not eligible. history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.